Cargando…

Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer

Detalles Bibliográficos
Autores principales:	Kurozumi, Sasagu, Katayama, Ayaka, Shirabe, Ken, Horiguchi, Jun, Rakha, Emad A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555688/ https://www.ncbi.nlm.nih.gov/pubmed/34733421 http://dx.doi.org/10.18632/oncotarget.28007

Ejemplares similares

Clinicopathological values of PD-L1 expression in HER2-positive breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

Prognostic value of tumor-infiltrating lymphocytes in estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer
por: Honda, Chikako, et al.
Publicado: (2021)

Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
por: Kurozumi, Sasagu, et al.
Publicado: (2016)

Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer
por: Katayama, Ayaka, et al.
Publicado: (2021)

Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2022)

Carboxypeptidase A4 accumulation is associated with an aggressive phenotype and poor prognosis in triple-negative breast cancer
por: Handa, Tadashi, et al.
Publicado: (2019)

Phase II study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer
por: Yanai, Keiko, et al.
Publicado: (2020)

Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index
por: Kurozumi, Sasagu, et al.
Publicado: (2017)

Prognostic significance of tumour-infiltrating lymphocytes for oestrogen receptor-negative breast cancer without lymph node metastasis
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab
por: Kurozumi, Sasagu, et al.
Publicado: (2015)

Prognostic significance of microinvasion with ductal carcinoma in situ of the breast: a meta-analysis
por: Shiino, Sho, et al.
Publicado: (2022)

The pathological complete response and secreted protein acidic and rich in cysteine expression in patients with breast cancer receiving neoadjuvant nab-paclitaxel chemotherapy
por: Nakazawa, Yuko, et al.
Publicado: (2020)

Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2018)

Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets
por: Kurozumi, Sasagu, et al.
Publicado: (2020)

Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2020)

Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
por: Aleskandarany, Mohammed A, et al.
Publicado: (2012)

The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2019)

Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysis
por: Shiino, Sho, et al.
Publicado: (2021)

Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases
por: Rakha, Emad A., et al.
Publicado: (2021)

Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair
por: Johnston, Simon J., et al.
Publicado: (2018)

The Effects of Low HER2/neu Expression on the Clinicopathological Characteristics of Triple-Negative Breast Cancer Patients
por: Dehghani, Mehdi, et al.
Publicado: (2020)

Clinicopathologic characteristics of HER2-positive pure mucinous carcinoma of the breast
por: Jang, Yunjeong, et al.
Publicado: (2020)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Fibrocystic breast disease with pleomorphic calcifications and segmental distribution: A case report
por: JiueLan, Kuo, et al.
Publicado: (2023)

Analysis of clinicopathological characteristics and prognostic factors of early‐stage human epidermal growth factor receptor 2 (HER2)‐low breast cancer: Compared with HER2‐0 breast cancer
por: Wu, Qian, et al.
Publicado: (2023)

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
por: Atallah, N. M., et al.
Publicado: (2023)

Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer
por: Kariri, Yousif A., et al.
Publicado: (2019)

Refining the definition of HER2‐low class in invasive breast cancer
por: Atallah, Nehal M, et al.
Publicado: (2022)

Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification
por: Powe, Desmond G, et al.
Publicado: (2009)

Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival
por: Joseph, Chitra, et al.
Publicado: (2020)

Analysis of the clinicopathological characteristics and prognosis of triple-positive breast cancer and HER2-positive breast cancer—A retrospective study
por: Ma, Dongxu, et al.
Publicado: (2023)

Pre- and Post-Neoadjuvant Clinicopathological Parameters Can Help in the Prognosis and the Prediction of Response in HER2+ and Triple Negative Breast Cancer
por: Pons, Laura, et al.
Publicado: (2023)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

The frequency and clinical significance of centromere enumeration probe 17 alterations in human epidermal growth factor receptor 2 immunohistochemistry‐equivocal invasive breast cancer
por: Katayama, Ayaka, et al.
Publicado: (2022)

mRNA expression of delta-HER2 and its clinicopathological correlation in HER2-overexpressing breast cancer
por: Wada, Ryuichi, et al.
Publicado: (2016)

Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
por: Yang, Liu, et al.
Publicado: (2022)

HER2 Positive and HER2 Negative Classical Type Invasive Lobular Carcinomas: Comparison of Clinicopathologic Features
por: He, Lin, et al.
Publicado: (2021)

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
por: Hosonaga, Mari, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_u63ti3mjp0lmo46l0pquiad8l7